Status
Conditions
Treatments
About
This study will evaluate the fluctuations of exhaled breath markers in patients with severe asthma on biologics. In the study, severe asthma patients will be followed up to 16 weeks monitoring lung function and inflammation through non-invasive technologies such as exhaled breath analysis (FeNO, GC-MS and EBC). A control group will be followed up to two weeks with the overall objective to indentify and evaluate the modifcations of markers of inflammation in patient under biologic treatment.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
100 participants in 2 patient groups
Loading...
Central trial contact
Carmen Durante; Stefania Principe, PhD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal